Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2026)

Corcept Therapeutics (CORT) has 9 years of Other Non-Current Liabilities data on file, last reported at $15.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 7.57% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (up 7.57% YoY), and the FY2025 full-year result was $15.2 million, up 7.75% from the prior year.
• Other Non-Current Liabilities improved to $15.3 million in Q1 2026, from $15.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $15.7 million in Q2 2025 to a low of $2.5 million in Q1 2022.
• A 5-year average of $11.1 million and a median of $10.9 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 2124.21% in 2022 and grew 7.57% in 2026, its largest moves.
• Tracing CORT's Other Non-Current Liabilities over 5 years: stood at $9.1 million in 2022, then climbed by 13.3% to $10.3 million in 2023, then jumped by 36.64% to $14.1 million in 2024, then rose by 7.75% to $15.2 million in 2025, then rose by 1.03% to $15.3 million in 2026.
• Business Quant data shows CORT's Other Non-Current Liabilities at $15.3 million in Q1 2026, $15.2 million in Q4 2025, and $14.1 million in Q3 2025.